Form 8-K for CALYPTE BIOMEDICAL CORP
--------------------------------------------------
3-Jun-2004
Other Events and Financial Statements & Exhibits
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant (the "Company") on March 19, 2004 amended its prioragreement with Marr Technologies, B.V. ("Marr"), the Company's largeststockholder, whereby Marr agreed to purchase up to $15,000,000 of 5% PromissoryNotes (the "Promissory Notes") that the Company could issue between March 19,2004 and May 31, 2004. The Company did not issue any Promissory Notes duringthis period. On May 26, 2004, the Company entered into a second amendment to theagreement with Marr whereby Marr has now committed to purchase up to anaggregate of $5,000,000 of the Company's Promissory Notes, subject toadjustment, and has extended the availability period of the commitment throughDecember 31, 2004. The second amendment also provides that any notes issuedunder the agreement between June 1, 2004 and December 31, 2004 will bearinterest at a rate of 9% per annum. The Company may, but is not required to,issue up to the entire $5,000,000 commitment of 9% Promissory Notes under thesecond amendment to the agreement. Any 9% Promissory Note issued by the Companyunder the second amendment to the agreement will have a maturity date of May 31,2005. Proceeds from any issuance of the notes under the second amendment to theagreement may be used for general corporate purposes.
In consideration of the extension of the availability period in thesecond amendment to the agreement, the Company granted Marr a warrant topurchase 500,000 shares of the Company's common stock at an exercise price of$0.40 per warrant share with piggyback registration rights for the underlyingshares of common stock. The warrant may be exercised by Marr for a period of twoyears from the effective date of the second amendment.
The Company hereby incorporates by reference the original agreement withMarr previously filed as an exhibit 10.134 to its Form 10-QSB for the periodended September 30, 2003 and the first amendment to the agreement with Marrfiled as exhibit 10.138 to its Form 8-K dated March 19, 2004.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
Exhibit No. Description
10.144 Amendment No.2 to Agreement for Commitment to Purchase Aggregate of $10,000,000 of 5% Promissory Notes between the Company and Marr Technologies, B.V. effective May 26, 2004.
10.145 Common Stock Purchase Warrant to Purchase 400,000 Shares of Common Stock issued by the Company to Marr Technologies BV dated May 26, 2004.
|
n von Caly.Wasn los hier? Nix. Naja, wird schon wieder, sobald der erste Großauftrag unterschrieben ist. Kann mir mal jemand die News übersetzen von vorgestern bitte. Nur kurz worums geht.Danke 
